Comunicati Stampa
Salute e Benessere

Minaris Advanced Therapies Opens New State-of-the-Art GMP Facility to Support Global Cell and Gene Therapy Growth

The site includes: The site includes: "The opening of this facility marks an important milestone in our mission to accelerate the development and manufacturing of transformative cell and gene therapies globally," saidDr. Orla Cloak, Chief Executive Officer of Minaris Advanced Therapies. "It enhances our European footprint and enhances our ability to meet client needs with speed, quality, and scalability." "This facility embodies our shared vision for the future of cell and gene therapy...
MUNICH, (informazione.news - comunicati stampa - salute e benessere)

The site includes:

"The opening of this facility marks an important milestone in our mission to accelerate the development and manufacturing of transformative cell and gene therapies globally," said , Chief Executive Officer of Minaris Advanced Therapies. "It enhances our European footprint and enhances our ability to meet client needs with speed, quality, and scalability."

"This facility embodies our shared vision for the future of cell and gene therapy manufacturing—scalable, flexible, and globally integrated," said , Chairman of the Board, Minaris Advanced Therapies. "The seamless transition into this new facility is a testament to the dedication of our team in Germany and the commitment Minaris Advanced Therapies has to bring long-term value to clients and patients worldwide."

Minaris hosted an opening celebration at the new site on Thursday, July 31 .


Minaris Advanced Therapies is a global contract development and manufacturing organization and contract testing provider with a focus on cell and gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania , and has more than 650,000 square feet of infrastructure across the United States, Europe and Asia. The organization has manufactured and released over 7,500 GMP batches and has a global network that supports therapy developers through early-stage development, clinical trials and commercial manufacturing.

Minaris Advanced Therapies is a portfolio company of Altaris.


Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare sub-sectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit 

Media Contact:
Tihesha Aaron
corp.communications@minaris.com

Photo - https://mma.prnewswire.com/media/2742929/image__7.jpg 

Logo - https://mma.prnewswire.com/media/2679651/Minaris_Advanced_Therapies_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/minaris-advanced-therapies-opens-new-state-of-the-art-gmp-facility-to-support-global-cell-and-gene-therapy-growth-302519870.html

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili